期刊文献+

二甲双胍对低级别非侵袭性膀胱肿瘤细胞增殖的影响 被引量:2

Effects of Metformin on the Proliferation of Noninvasive Low-grade Bladder Cancer Cells
原文传递
导出
摘要 目的:初步探讨降糖药物二甲双胍对膀胱肿瘤细胞253J的作用及其相关作用机制。方法:采用Cell Counting Kit-8(CCK-8)试剂盒分析二甲双胍对膀胱肿瘤细胞增殖的影响。应用流式细胞仪检测二甲双胍对细胞周期及凋亡的影响。并通过免疫印迹方法检测相关蛋白确定可能参与其中的信号分子。结果:在各时间点(24小时,48小时,72小时)二甲双胍处理组与对照组相比膀胱肿瘤细胞的增殖受到明显抑制(P<0.01或P<0.05);与对照组比较,二甲双胍处理组G0/G1期细胞比例上升,S期细胞比例下降(P<0.01或P<0.05);免疫蛋白印迹发现,二甲双胍处理组中的磷酸化AMP激活的蛋白激酶(AMP-activated protein kinase,AMPK)表达升高,同时细胞周期蛋白D1(cyclin D1)的表达下降(P<0.01或P<0.05)。结论:体外实验中二甲双胍能够明显抑制膀胱肿瘤细胞的增殖,通过下调cyclin D1的表达诱导细胞周期停滞于G0/G1期。这些结果表明二甲双胍可能成为治疗膀胱癌的潜在药物。 Objective: To evaluate the effects of metformin on human bladder cancer cell line 253J and its underlying mechanisms. 'Method.s: Cell Counting Kit-8 (CCK-8) was used to investigate the effects of metformin on 253J cells growth. Flow cytometry was used to evaluate the cell cycle changes after metformin treatment. The possible signaling molecules involved in this process were determined by immunoblot analysis of various proteins. Results: In 24 h, 48 h, and 72 h, the proliferation of bladder cancer cells was significantly inhibited compared with that in control group (P 〈0.01 or P 〈0.05); Compared with control group, a significant increase was observed in the percentage of cells in the G0/G1 phases. In parallel, there was a reduction in the percentage of cells in the S and G2/M phases (P 〈0.01 or P 〈0.05). Western blot analysis found that the expression ofphosphorylated AMP-activated protein kinase (AMP-activated protein kinase, AMPK) increased, while the expression of cyclin D 1 decreased in metforrnin-treated group.(P 〈0.01 or P 〈0.05). Conclusion: Metformin can induce G0/GI cell cycle arrest and inhibit 253J cells proliferation in vitro, suggesting that metforrnin may be a potential therapeutic drug for the treatment of human bladder cancer.
出处 《现代生物医学进展》 CAS 2015年第12期2209-2212,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81170642)
关键词 二甲双胍 膀胱癌 AMP激活的蛋白激酶 细胞周期 细胞周期蛋白D1 Metforrnin Bladder cancer AMPK Cell cycle CyclinD 1
  • 相关文献

参考文献20

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA: a cancer journal for clinicians, 2013, 63(1): 11-30.
  • 2Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. European urology, 2011, 59( 6): 997-1008.
  • 3Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines [J]. European urology, 2011, 59(6): 1009-1018.
  • 4Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis [J], PloS one. 2012, 7(3): e33411.
  • 5Zhang T, Guo P, Zhang Y, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo [J]. lnt J Mol Sci, 2013, 14(12): 24603-24618.
  • 6Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non muscle invasive bladder cancer [J]. BJU international, 2013, 112(8): 1105-1112.
  • 7Rattan R, Graham RP, Maguire JL, et al. Mefformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo[J]. Neoplasia, 2011, 13(5): 483-491.
  • 8Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease ofcyclin D1 level[J]. Oneogene, 2008, 27(25): 3576-3586.
  • 9Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo [J]. Mol Cancer Ther, 2012, 11 (3): 549-560.
  • 10Cai X, Hu X, Cai B, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin DI in vitro and in vivo[J]. Oncol Rep, 2013, 30(5): 2449-2457.

二级参考文献11

  • 1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010,362:1090-1101.
  • 2Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. JAMA, 2008, 300:2754-2764.
  • 3Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer. Diabetes Care, 2009,32 : 1620-1625.
  • 4Landman GWD, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care, 2010,33:322-326.
  • 5Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of mefformin action. J Clin Invest, 2001,108 : 1167-1174.
  • 6Li J, Jiang P, Robinson M, et al. AMPK-betal subunit is a p53- independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis, 2003,24:827-834.
  • 7Zakikhani M, Dowling R, Fantus IG, et al. Mefformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 2006,66 : 10269-10273.
  • 8Stacey DW. CyclinD1 serves as a cell cycle regulatory switch in actively proliferating cells. Curt Opin Cell Biol, 2003,15 : 158-163.
  • 9Culotta E, Koshland DE. P53 sweeps through cancer research. Science, 1993,262 : 1958-1961.
  • 10Pereda MP, Ledda MF, Goldberg V, et al. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary ceils. J Clin Endocrinol Metab, 2000,85:263-269.

共引文献3

同被引文献21

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部